# The Phase I Study of HS-10509 in Chinese Adult Subjects

> **NCT06301074** · PHASE1 · UNKNOWN · sponsor: **Jiangsu Hansoh Pharmaceutical Co., Ltd.** · enrollment: 80 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** HS-10509
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06301074
- **Lead sponsor:** Jiangsu Hansoh Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-03
- **Primary completion:** 2024-05
- **Final completion:** 2024-10
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2024-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06301074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06301074, "The Phase I Study of HS-10509 in Chinese Adult Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06301074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*